NEW YORK (GenomeWeb News) – MDxHealth and Bostwick Laboratories today announced a marketing agreement covering MDxHealth's ConfirmMDx prostate cancer test.
The deal, they said, provides MDxHealth with access to one of the largest urology networks in the US. Bostwick specializes in anatomic and clinical pathology.
Financial and other terms of the deal were not disclosed.
"With their national reach and strong reputation, Bostwick Laboratories is an ideal partner to help us continue building upon the momentum we have achieved to date, raising awareness and access to ConfirmMDx within the urology community," MDxHealth CEO Jan Groen said in a statement.
ConfirmMDx helps clinicians differentiate patients with true negative biopsies from those at risk for occult cancer. MDxHealth received approval from the State of New York for ConfirmMDx earlier this month, making the epigenetics-based test available in all 50 states in the US.